The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs

被引:40
作者
Kogushi, Motoji [1 ]
Matsuoka, Toshiyuki [1 ]
Kawata, Tsutomu [1 ]
Kuramochi, Hiroko [1 ]
Kawaguchi, Shinki [1 ]
Murakami, Kimiyo [1 ]
Hiyoshi, Hironobu [1 ]
Suzuki, Shuichi [1 ]
Kawahara, Tetsuya [1 ]
Kajiwara, Akiharu [1 ]
Hishinuma, Ieharu [1 ]
机构
[1] Eisai & Co Ltd, Eisai Tsukuba Res Labs, Tsukuba, Ibaraki 3002635, Japan
关键词
Protease-activated receptor-1 antagonist; E5555; Platelet; Aggregation; Thrombosis; Bleeding time; DOUBLE-BLIND; PLATELET; POTENT; ANTIPLATELET; ACTIVATION; MECHANISM; THERAPY; CLONING; MODEL;
D O I
10.1016/j.ejphar.2011.01.058
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Thrombin is a powerful agonist for platelets, the action of which is mediated by the thrombin receptor protease-activated receptor-1 (PAR-1). Recently, we discovered that E5555 (1-(3-tert-butyl-4-methoxy-5-morpholinophenyl)-2-(5,6-diethoxy-7-fluoro-1-imino-1,3-dihydro-2H-isoindol-2-yl) ethanone hydrobromide) is a potent thrombin receptor antagonist. We evaluated the anti-platelet and anti-thrombotic effects of E5555. E5555 inhibited the binding of a high-affinity thrombin receptor-activating peptide ([H-3]haTRAP) to PAR-1 with a half maximal inhibitory concentration (IC50) value of 0.019 mu M. E5555 showed potent inhibitory effects on human platelet aggregation induced by thrombin and TRAP with IC50 values of 0.064 and 0.0311 mu M, respectively, but had no effect on platelet aggregation induced by either ADP or collagen. Similarly, E5555 showed potent and selective inhibitory effects on guinea pig platelet aggregation induced by thrombin and TRAP with IC50 values of 0.13 and 0.097 mu M, respectively. The antithrombotic activity of E5555 in vivo was evaluated in a photochemically-induced thrombosis (PIT) model using guinea pigs. Oral administration of E5555 at 30 and 100 mg/kg prolonged the time to occlusion by 1.8-fold and 2.4-fold, respectively, compared with controls. Furthermore, E5555 did not prolong bleeding time in guinea pigs at the highest tested dosage of 1000 mg/kg. The drug interactions between E5555 and tissue plasminogen activator (tPA) were evaluated. Intravenous administration of 1 mg/kg tPA significantly prolonged bleeding time, and its effects were not altered by the oral co-administration of 300 mg/kg E5555. These results suggest that E5555 could be a therapeutic option for atherothrombotic disease. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:131 / 137
页数:7
相关论文
共 31 条
[11]   Basic and Translational Research on Proteinase-Activated Receptors: Antagonism of the Proteinase-Activated Receptor 1 for Thrombin, a Novel Approach to Antiplatelet Therapy for Atherothrombotic Disease [J].
Chintala, Madhu ;
Shimizu, Kenji ;
Ogawa, Masami ;
Yamaguchi, Hiroya ;
Doi, Masaki ;
Jensen, Peder .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2008, 108 (04) :433-438
[12]  
CONNOLLY TM, 1994, THROMB HAEMOSTASIS, V72, P627
[13]   AN ANTIBODY AGAINST THE EXOSITE OF THE CLONED THROMBIN RECEPTOR INHIBITS EXPERIMENTAL ARTERIAL THROMBOSIS IN THE AFRICAN-GREEN MONKEY [J].
COOK, JJ ;
SITKO, GR ;
BEDNAR, B ;
CONDRA, C ;
MELLOTT, MJ ;
FENG, DM ;
NUTT, RF ;
SHAFER, JA ;
GOULD, RJ ;
CONNOLLY, TM .
CIRCULATION, 1995, 91 (12) :2961-2971
[14]   Mechanisms of disease:: Platelet activation and atherothrombosis [J].
Davi, Giovanni ;
Patrono, Carlo .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (24) :2482-2494
[15]   Design and evaluation of potent peptide-mimetic PAR1 antagonists [J].
Derian, CK ;
Maryanoff, BE ;
Andrade-Gordon, P ;
Zhang, HC .
DRUG DEVELOPMENT RESEARCH, 2003, 59 (04) :355-366
[16]   Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates [J].
Derian, CK ;
Damiano, BP ;
Addo, MF ;
Darrow, AL ;
D'Andrea, MR ;
Nedelman, M ;
Zhang, HC ;
Maryanoff, BE ;
Andrade-Gordon, P .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (02) :855-861
[17]   DEVELOPMENT OF A POTENT THROMBIN RECEPTOR-LIGAND [J].
FENG, DM ;
VEBER, DF ;
CONNOLLY, TM ;
CONDRA, C ;
TANG, MJ ;
NUTT, RF .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (20) :4125-4130
[18]   Atherothrombosis and high-risk plaque Part I: Evolving concepts [J].
Fuster, V ;
Moreno, PR ;
Fayad, ZA ;
Corti, R ;
Badimon, JJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (06) :937-954
[19]   Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease [J].
Goto, Shinya ;
Ogawa, Hisao ;
Takeuchi, Masaru ;
Flather, Marcus D. ;
Bhatt, Deepak L. .
EUROPEAN HEART JOURNAL, 2010, 31 (21) :2601-2613
[20]   Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin [J].
Kahn, ML ;
Nakanishi-Matsui, M ;
Shapiro, MJ ;
Ishihara, H ;
Coughlin, SR .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (06) :879-887